Transcriptomics

Dataset Information

0

Losartan controls immune checkpoint blocker-induced edema and improves survival in glioblastoma


ABSTRACT: Immune checkpoint blockers (ICBs) have failed in all Phase III glioblastoma trials. Here, we found that ICBs induce cerebral edema in some patients and mice with glioblastoma. Through single-cell RNA sequencing, intravital imaging, and T cell blocking studies in mice, we demonstrated that this edema results from an inflammatory response following anti-PD1 antibody treatment that disrupts the blood-tumor-barrier. Used in lieu of immunosuppressive corticosteroids, the angiotensin receptor blocker losartan prevented this ICB-induced edema and reprogrammed the tumor microenvironment, curing 20% of mice which increased to 40% in combination with standard of care treatment. Using a bihemispheric tumor model, we identified a “hot” tumor immune signature prior to losartan+anti-PD1 therapy that predicted long-term survival. Our findings provide the rationale and associated biomarkers to test losartan with ICBs in glioblastoma patients.

ORGANISM(S): Mus musculus

PROVIDER: GSE212246 | GEO | 2023/01/01

REPOSITORIES: GEO

Dataset's files

Source:
Action DRS
Other
Items per page:
1 - 1 of 1

Similar Datasets

| PRJNA874707 | ENA
2010-09-23 | E-GEOD-18298 | biostudies-arrayexpress
2010-09-23 | GSE18298 | GEO
| S-EPMC9963691 | biostudies-literature
2021-01-30 | GSE109861 | GEO
2006-10-24 | GSE4712 | GEO
| PRJNA937218 | ENA
| PRJDB11353 | ENA
2022-02-05 | GSE195981 | GEO
| PRJNA736237 | ENA